« Old Blood Reported to Increase Heart Surgery Morbidity | Main | Metabolomics, Metabolomic Profiling, and Systems Biology »

Comments

Dr Radcliffe herceptin her2

The companion techique should be well researched and studied before allowing
with Herceptin

Paul Epner

I read with interest your views on the use of the term "companion diagnostics." I am also concerned that it is too imprecise, however I would suggest that we consider other accepted terms as a basis for new jargon. In this case, I refer to therapeutic drug monitoring (TDM) which leads me to think that the appropriate term here would be "therapeutic drug assessment (TDA)" or slightly more distant, "drug effectiveness assessment (DEA)", the latter having a possibly confusing acronym. I am less worried about the industry relationships. Failure to provide valid TDA's increases clinical and economic risks for healthcare consumers. History has shown that development of TDM's through industry relationships has been beneficial.

The comments to this entry are closed.

Corporate Underwriters





  •  

     
     
     
     
     

Search Lab Soft News

  • Google

    WWW
    labsoftnews.typepad.com

Subscribe to Lab Soft News (Email and RSS Feeds)

Your email address:


Powered by FeedBlitz

June 2017

Sun Mon Tue Wed Thu Fri Sat
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30  
Blog powered by Typepad
Member since 12/2005